Abstract
The prevalence of cardiovascular diseases treated by coronary stents (especially those with Drug Eluting Stent) has been rising worldwide. Nonaspirin antiplatelet agents such as thienopyridines (clopidogrel, ticlopidine), which inhibit platelet activation, adhesion, or aggregation, are used in the management of coronary artery diseases. The subsequent increase in consumption of anticoagulants and thienopyridines now brings into question whether resuming these medical therapies after temporarily discontinuing them for endoscopic resection furthers the risk of delayed bleeding.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
